Harbor
Claim my $200
GLP-1 MedicationsMarch 13, 2026

The Complete Guide to FDA-Approved Weight Loss Medications in 2026

The Complete Guide to FDA-Approved Weight Loss Medications in 2026

The weight-loss medication landscape has changed more in the past 18 months than in the previous 2 decades combined. Between the FDA's approval of the first oral GLP-1 pill for weight management, a landmark federal program poised to bring these drugs to millions of Medicare and Medicaid beneficiaries, and a pipeline of next-generation therapies promising even greater efficacy, 2026 marks a genuine inflection point for anyone considering pharmacological support for weight loss. Yet with so many options now available, the sheer volume of information can feel paralyzing. What's actually FDA-approved right now? How do these medications compare head-to-head? What will they cost you? And what should you realistically expect once you start, or stop, taking them? This guide consolidates the full 2026 landscape into a research-backed resource.

Every FDA-Approved Weight Loss Medication Available Right Now

Long-Term Medications

Semaglutide (Wegovy) — Injectable and Oral

Wegovy remains the most widely recognized name in weight loss pharmacology, and for good reason. The injectable version, approved in 2021, demonstrated average weight loss of 15–16% of body weight in clinical trials. But the bigger story in 2026 is the oral Wegovy pill, approved by the FDA on December 22, 2025, following positive results from the OASIS 4 phase 3 clinical trial. This makes it the first and only oral GLP-1 medication approved for chronic weight management.

Weight loss meds notebook labeled "Weight Loss Program" displayed beside a yellow tape measure, pen, halved avocado, and bowl of chia seeds on a gray surface

In patients who adhered fully to treatment, the 25 mg oral dose produced a mean weight loss of 16.6% at 64 weeks, with 34.4% of adherent participants achieving 20% or greater weight loss. Novo Nordisk began the full U.S. commercial rollout in January 2026, with starting doses of 1.5 mg tablets. A critical practical advantage: the pill doesn't require refrigeration, unlike its injectable counterpart.

Tirzepatide (Zepbound)

This is currently the most effective FDA-approved weight loss medication on the market. As a dual GIP/GLP-1 receptor agonist, meaning it activates two appetite-regulating pathways instead of one, clinical trials showed average weight loss of up to 22.5% of body weight. According to trial data, 89% of tirzepatide users lost at least 10% of their body weight, compared to 69% of semaglutide users. Zepbound is approved for adults with obesity (BMI ≥30) or those who are overweight (BMI ≥27) with at least one weight-related condition.

Liraglutide (Saxenda)

Saxenda was the first GLP-1 receptor agonist approved for weight management, hitting the market in 2014. It's a daily injection and produces more modest weight loss, typically in the 5–8% range. While it's been largely overshadowed by semaglutide and tirzepatide, Saxenda remains relevant as an option for patients who don't tolerate the newer drugs or for adolescents aged 12 and older.

Naltrexone-Bupropion (Contrave)

Contrave combines an antidepressant (bupropion) with an opioid antagonist (naltrexone) to reduce appetite and cravings. It works through a completely different mechanism than GLP-1 drugs, targeting the brain's reward system rather than gut hormones. Average weight loss is more modest, roughly 5–6% of body weight, but it may be appropriate for patients who can't use injectable medications or who have concurrent mood-related eating patterns.

Phentermine-Topiramate (Qsymia)

Approved in 2012, Qsymia combines a stimulant appetite suppressant with an anticonvulsant. It delivers an average weight loss of roughly 8–10%, making it one of the more effective non-GLP-1 options. However, it carries a boxed warning for birth defects and requires a negative pregnancy test before and during treatment. It's available only through certified pharmacies under a Risk Evaluation and Mitigation Strategy (REMS) program.

Orlistat (Xenical / Alli)

Orlistat works entirely differently from every other drug on this list. Instead of suppressing appetite, it blocks fat absorption in the gut, roughly 30% of dietary fat passes through undigested. Average weight loss is modest (3–5% of body weight), and the gastrointestinal side effects (oily stools, urgency, flatulence) limit tolerability for many patients. The over-the-counter version, Alli, is available at a lower 60 mg dose without a prescription.

Short-Term Medications (Less Than 12 Weeks)

The FDA has approved several older stimulant-based appetite suppressants for short-term use, including phentermine (Adipex-P, Lomaira), diethylpropion, benzphetamine, and phendimetrazine. These drugs work by increasing norepinephrine levels, which reduces hunger signals. They're generally prescribed as a bridge rather than as a standalone solution.

Weight loss medications progress tracked by a person in gray leggings standing barefoot on a white bathroom scale

Specialty Medication

Setmelanotide (Imcivree) is FDA-approved for a narrow but important population: people with obesity caused by specific rare genetic disorders affecting the MC4R pathway. It's approved for adults and children ages 2 and above and works by restoring the body's satiety signaling, which these genetic conditions disrupt.

The Oral Wegovy Pill: Why It Changes the Conversation

The December 2025 approval of the Wegovy pill deserves its own discussion because it addresses the single biggest barrier that kept millions of patients from trying GLP-1 therapy: needle aversion. A significant percentage of patients eligible for injectable GLP-1s decline treatment specifically because of injection anxiety. The oral formulation eliminates that barrier entirely. But the advantages extend beyond psychology:

  • Cost is dramatically lower. Novo Nordisk priced the oral Wegovy pill at approximately $149 per month without insurance, a fraction of the $1,000+ monthly list price of injectable Wegovy. With insurance, co-pays drop to roughly $25 or less. This is a structural shift in accessibility.
  • Storage is simpler. Injectable Wegovy requires refrigeration before first use. The oral pill does not require it, which makes travel and pharmacy logistics significantly easier.
  • Efficacy is comparable. The 16.6% mean weight loss at 64 weeks is slightly lower than the injectable's ~15–16% in the STEP trials, which measured only adherent patients, making a direct comparison complex.

The pill does come with specific dosing requirements — it must be taken on an empty stomach with a small amount of water, and patients need to wait at least 30 minutes before eating or drinking anything else. This protocol maximizes absorption of the active ingredient.

How These Medications Actually Compare: Efficacy by the Numbers

Choosing between medications isn't just about picking the one with the highest weight-loss percentage. Tolerability, mechanism of action, delivery format, and individual response all matter. But the efficacy data provide a useful starting framework.

Tirzepatide (Zepbound) leads the field with up to 22.5% mean body weight loss. Semaglutide injectable (Wegovy) follows at approximately 15–16%. Oral semaglutide (Wegovy pill) achieves 16.6% in adherent patients. Phentermine-topiramate (Qsymia) delivers roughly 8–10%. Naltrexone-bupropion (Contrave) produces about 5–6%. Liraglutide (Saxenda) falls in the 5–8% range. Orlistat (Xenical) averages 3–5%.

GLP-1 medications appear comparably effective across age, race, ethnicity, and starting BMI. However, the study did find a gender difference. Women who took GLP-1 receptor agonists lost about 11% of their starting weight on average, compared to about 7% among men. Observed weight reduction in clinical practice tends to be lower than in randomized controlled trials. The discontinuation rates of 20–50% within the first year significantly impact average outcomes. Patients who stick with the treatment approach show trial-level results.

Side Effects and Safety: What the Research Actually Shows

GLP-1 receptor agonists share a common side-effect profile, dominated by gastrointestinal symptoms. Up to 50% of patients experience nausea, particularly during the dose-escalation phase. Vomiting, diarrhea, and constipation are also common. For most patients, these symptoms are transient and diminish as the body adjusts over the first 4–8 weeks.

The more serious risks deserve careful attention. GLP-1 medications are associated with increased risk of pancreatitis, kidney conditions, and certain gastrointestinal complications, including gastroparesis and, rarely, bowel obstruction. These events are uncommon but not negligible, which is why ongoing medical supervision during treatment is essential.

"Ozempic face" entered the cultural lexicon as a term for the facial volume loss that can accompany rapid, significant weight loss on GLP-1 drugs. This isn't a drug-specific side effect per se; it's a consequence of substantial fat loss, including in the face. It's more pronounced in older patients and those who lose weight very quickly. For patients exploring medication options, the value of working with a physician who specializes in weight management cannot be overstated. Platforms like Harbor pair patients with licensed U.S. physicians who can monitor for side effects, adjust dosing, and provide the ongoing clinical oversight that turns a prescription into a structured treatment plan, including support from a registered dietitian to build sustainable habits beyond medication.

Managing Common Side Effects

Harvard Health and the Cleveland Clinic both recommend practical strategies: eating smaller, more frequent meals; avoiding strong-smelling or high-fat foods during the dose-escalation period; staying well hydrated; and starting with the lowest effective dose and titrating slowly. These simple adjustments resolve nausea for the majority of patients without requiring medication changes.

FDA-approved weight loss medications discussed by a white-coat doctor holding a tape measure and green apple at a clinical desk with a stethoscope and clipboard

The Weight Regain Problem: What Happens When You Stop

Weight regain after discontinuing GLP-1 therapy is significant and rapid. Patients who stopped semaglutide or tirzepatide regained an average of 9.9 kg in the first year. In the STEP-10 trial, over 40% of lost weight was regained within just 28 weeks of stopping semaglutide. In SURMOUNT-4, more than 50% of tirzepatide-related weight loss rebounded over 52 weeks. All participants would return to their baseline weight approximately 1.5 to 1.7 years after stopping any weight-loss medication.

This is a reflection of the biological reality that obesity involves chronic changes in appetite regulation, metabolism, and hormonal signaling. Just as blood pressure medication controls hypertension without curing it, GLP-1s manage obesity while you take them. Stopping treatment allows the underlying biology to reassert itself.

The BALANCE Model: How Medicare and Medicaid Coverage Is Changing

For years, cost has been the single largest barrier to access to GLP-1s. Monthly prices exceeding $1,000 put these medications out of reach for most Americans without generous insurance coverage. The federal government's BALANCE Model, Better Approaches to Lifestyle and Nutrition for Comprehensive Health, represents the most significant policy shift to date. Announced in December 2025 by the Centers for Medicare & Medicaid Services (CMS), the BALANCE Model has several key components:

  • Medicare Part D beneficiaries are expected to gain access to GLP-1 medications by July 2026 through a short-term demonstration program, with full model participation by Part D plans beginning in January 2027. Eligible beneficiaries will pay approximately $50 per month for GLP-1 medications.
  • State Medicaid agencies can join the model starting in May 2026. As of January 2026, only 13 state Medicaid programs cover GLP-1s for obesity treatment, and four states actually eliminated coverage recently due to budget pressures. The BALANCE Model aims to reverse this trend by having CMS negotiate drug pricing directly with manufacturers on behalf of participating states and plans.
  • Mandatory lifestyle support is baked into the model. All beneficiaries receiving GLP-1s through BALANCE will also have access to a lifestyle support program that covers nutrition education, weight maintenance strategies, and healthy habit formation.

Participation is voluntary at every level: manufacturers, states, and insurance plans must all opt in. This means coverage expansion won't be uniform across the country. But the model's structure signals a fundamental shift in how the federal government views obesity treatment.

What's Coming Next: The 2026–2027 Pipeline

The medications available today are likely just the beginning. Several next-generation therapies in late-stage development could reshape the field again within the next 12–24 months:

  • Orforglipron (Eli Lilly) is a small-molecule oral GLP-1 receptor agonist, meaning it doesn't require the special empty-stomach dosing protocol of oral Wegovy. It can be taken with food, which dramatically simplifies the patient experience. An FDA decision is expected in April 2026, and phase 3 data showed mean body weight reductions of 7.5% (6 mg), 8.4% (12 mg), and 11.2% (36 mg) at 72 weeks.
  • CagriSema (Novo Nordisk) combines cagrilintide (an amylin analog) with semaglutide in a single weekly injection. Phase 3a results showed a mean weight loss of 20.4% at 68 weeks, approaching tirzepatide territory. Novo Nordisk filed for FDA approval in 2025.
  • Retatrutide (Eli Lilly) is a triple receptor agonist that targets GLP-1, GIP, and glucagon receptors simultaneously. Phase 3 TRIUMPH-4 trial results reported an average weight loss of up to 28.7%, the highest among any obesity drug in clinical development. Regulatory submission is expected in 2026.
  • Amycretin (Novo Nordisk) is a dual amylin and GLP-1 agonist available in both oral and injectable forms, with phase 2 results showing a remarkable 24.3% mean weight loss at just 36 weeks.

The pharmaceutical intelligence platform Ozmosi projects one to two new GLP-1-class drug launches per year starting in 2026, with the broader obesity market expected to exceed $100 billion globally by the end of the decade.

The medications reviewed in this guide are powerful tools, but they work best as one component of a comprehensive approach that includes nutritional changes, physical activity, behavioral support, and ongoing medical monitoring. The science is clear that pharmacology alone isn't a permanent fix, and equally clear that for millions of people with obesity, these drugs provide a degree of biological support that lifestyle changes alone cannot replicate. The 2026 landscape offers more options and better science than at any previous point in obesity medicine. The key is approaching it with eyes wide open and a plan that extends beyond the prescription.

Sources: